menu search

PFE / Pfizer's Sequel: Return Of The Value Stock

Pfizer's Sequel: Return Of The Value Stock
Pfizer is focusing on its core growth engines and strategic acquisitions, particularly in the oncology segment, to compensate for downgraded revenue projections and a concerning debt profile. The company's financial health is fragile, with a significant decrease in FY23 revenue and EPS outlook and a high total debt-to-liquid assets ratio. Market sentiment towards Pfizer is cautious, with modest growth expectations and underperformance compared to the broader market, but limited investor pessimism and a commitment to returning capital to shareholders through dividends. Read More
Posted: Oct 16 2023, 02:53
Author Name: Seeking Alpha
Views: 092169

PFE News  

Seeking High Dividends? 3 Fairly Valued/Undervalued High Dividend Yield Stocks For Your Portfolio

By Seeking Alpha
November 4, 2023

Seeking High Dividends? 3 Fairly Valued/Undervalued High Dividend Yield Stocks For Your Portfolio

High dividend yield companies are valuable assets for your portfolio, since they are a great way to generate added income, which you can reinvest or u more_horizontal

Should You Pick Pfizer Stock At $30?

By Forbes
November 3, 2023

Should You Pick Pfizer Stock At $30?

Pfizer (NYSE: PFE) reported its Q3 results earlier this week, with revenues missing but earnings beating the street estimates, and we believe that PFE more_horizontal

There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock?

By The Motley Fool
November 3, 2023

There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock?

Pfizer reported an adjusted loss of nearly $1 billion in the third quarter, and recently lowered its forecasts for coronavirus product sales. The comp more_horizontal

This High-Yield Dividend Stock Is a Proven Wealth Creator

By The Motley Fool
November 2, 2023

This High-Yield Dividend Stock Is a Proven Wealth Creator

In 2023, the broader market has ignored the deep value proposition of most large-cap pharmaceutical stocks. Pfizer, a stalwart of the industry, has be more_horizontal

UK regulator approves Pfizer's hair loss drug

By Reuters
November 1, 2023

UK regulator approves Pfizer's hair loss drug

Britain's medicines regulator on Wednesday approved Pfizer Inc's drug to treat hair loss caused by an autoimmune disease. more_horizontal

Pfizer Posted a Steep Loss. Is It Time to Sell?

By The Motley Fool
November 1, 2023

Pfizer Posted a Steep Loss. Is It Time to Sell?

Pfizer reported third-quarter results on Tuesday, Oct. 31. The company told investors it had to write down $5.6 billion worth of unused inventory in t more_horizontal

Pfizer quarterly results hit by soft demand for COVID-19 products

By Fox Business
October 31, 2023

Pfizer quarterly results hit by soft demand for COVID-19 products

Sales of the company's coronavirus vaccine Comirnaty dropped 70% during the third quarter compared with the same period a year earlier, Pfizer reporte more_horizontal

We are keen to join forces with Seagan, says Pfizer CEO Albert Bourla

By CNBC Television
October 31, 2023

We are keen to join forces with Seagan, says Pfizer CEO Albert Bourla

Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk Q3 earnings results, partnering with Kansas City Chiefs Tight End Trav more_horizontal


Search within

Pages Search Results: